An examination of the bidirectional relationship between functioning and symptom levels in patients with anxiety disorders in the CALM study

Psychological Medicine

Volumn 45, Issue 3, 2015, Pages 647-661

  Brown, L A ^a   Krull, J L ^a   Roy Byrne, P ^b   Sherbourne, C D ^c   Stein, M B ^d   Sullivan, G ^e,f   Rose, R D ^a   Bystritsky, A ^a   Craske, M G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e South Central VA Mental Illness Research Education and Clinical Center   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anxiety; functioning; primary care

Indexed keywords

ANXIOLYTIC AGENT;

ADULT; ANXIETY DISORDERS; COGNITIVE THERAPY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITIVE THERAPY; EXECUTIVE FUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84927603068     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714002062     Document Type: Article

References (56)

1. Akaike H (1976). An information criterion (AIC). Math Science 14, 5-9.
2. APA (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Publishing: Arlington, VA.
3. Arch JJ, Ayers CR (2013). Which treatmentworked better for whom?Moderators of group cognitive behavioral therapy versus adaptedmindfulness based stress reduction for anxiety disorders. Behaviour Research and Therapy 51, 434-442.
4. Arch JJ, Eifert GH, Davies C, Plumb JC, Rose RD, Craske MG (2012). Randomized trial of cognitive behavioral therapy versus acceptance and commitment therapy for the treatment of mixed anxiety disorders. Journal of Consulting and Clinical Psychology 80, 750-765.
5. Bentler PM (1995). EQS: Structural Equations Program Manual. Multivariate Software: Encino, CA.
6. Bentler PM, Bonett DG (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin 88, 588-606.
7. Chan S, Jia S, Chiu H, Chien W, Thompson DR, Hu Y, Lam L (2009). Subjective health-related quality of life in Chinese older persons with depression in Shanghai and Hong Kong: relationship to clinical factors, level of functioning, and social support. International Journal of Geriatric Psychiatry 24, 355-362.
8. Craske MG, Rose RD, Lang AJ, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne CD, Bystritsky A, Stein MB, Roy-Byrne P (2009). Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depression and Anxiety 26, 235-242.
9. Craske MG, Stein MB, Sullivan G, Sherbourne C, Bystritsky A, Rose RD, Lang AJ, Welch S, Campbell-Sills L, Golinelli D, Roy-Byrne P (2011). Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Archives of General Psychiatry 68, 378-388.
10. Derogatis LR (1994). Symptom Checklist-90-R (SCL-90-R): Administration, Scoring, and Procedures Manual. NCS: Minneapolis, MN.
11. Derogatis LR, Melisaratos N (1983). The Brief Symptom Inventory: an introductory report. Psychological Medicine 13, 595-605.
12. DuPont RL, Rice DP, Miller LS (1996). Economic costs of anxiety disorders. Anxiety 2, 167-172.
13. Fleishman J, Selim A, Kazis L (2010). Deriving SF-12v2 physical andmental health summary scores: a comparison of different scoring algorithms. Quality of Life Research 19, 231-241.
14. Hayes SC, Strosahl K, Wilson KG (1999). Acceptance and Commitment Therapy: an Experiential Approach to Behavior Change. Guilford Press: New York.
15. Hoehn-Saric R, McLeod DR, Hipsley PA (1993). Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology 13, 321-326.
16. Hox JJ, Maas CJM, Brinkhuis MJS (2010). The effect of estimation method and sampling size in multileve structural equation modeling. Statistica Neerlandica 64, 157-170.
17. Hu L, Bentler PM (1999). Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling 6, 1-55.
18. Jacobs RJ, Davidson JR, Gupta S, Meyerhoff AS (1997). The effectsof clonazepamonqualityof life andworkproductivity in panic disorder. American Journal of Managed Care 3, 1187-1196.
19. Katerndahl DA, Realini JP (1997). Quality of life and panic-relatedwork disability in subjectswith infrequent panic and panic disorder. Journal of Clinical Psychiatry 58, 153-158.
20. Kiliç C, Noshirvani H, Başoʇlu S, Marks I, (1997). Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. Psychotherapy and Psychosomatics 66, 175-178.
21. Kroenke K, Spitzer RL, Williams JBW (2001). The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine 16, 601-613.
22. Lecrubier Y, Judge R (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative paroxetine panic study investigators. Acta Psychiatrica Scandinavica 95, 153-160.
23. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997). Assessing psychiatric impairment in primary care with the sheehan disability scale. International Journal of Psychiatry in Medicine 27, 93-105.
24. Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Social Psychiatry and Psychiatric Epidemiology 27, 78-82.
25. Lochner C, Mogotsi M, du Toit PL, Kaminer D, Niehaus DJ, Stein DJ (2003). Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology 36, 255-262.
26. Maas CJM, Hox JJ (2004). The influence of violations of assumptions on multilevel parameter estimates and their standard error. Computational Statistics & Data Analysis 46, 427-440.
27. Malik ML, Connor KM, Sutherland SM, Smith RD, Davison RM, Davidson JR (1999). Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. Journal of Traumatic Stress 12, 387-393.
28. Maor Y, Olmer L, Mozes B (2001). The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients - the role of depression. Multiple Sclerosis 7, 131-135.
29. Mardia KV (1970). Measures of multivariate skewness and kurtosis with applications. Biometrika 57, 519-530.
30. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL (1989). Quality of life in panic disorder. Archives of General Psychiatry 46, 984-992.
31. Martens MP, Haase RH (2006). Advanced applications of structural equation modeling in counseling psychology research. The Counseling Psychologist 34, 806-838.
32. Mavissakalian M, Perel J, Talbott-Green M, Sloan C (1998). Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biological Psychiatry 43, 848-854.
33. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. American Journal of Psychiatry 155, 1570-1577.
34. Monson CM, Schnurr PP, Resick PA, Friedman MJ, Young-Xu Y, Stevens SP (2006). Cognitive processing therapy for veterans with military-related posttraumatic stress disorder. Journal of Consulting and Clinical Psychology 74, 898-907.
35. Moritz S, Rufer M, Fricke S, Karow A, Morfeld M, Jelinek L, Jacobsen D (2005). Quality of life in obsessive-compulsive disorder before and after treatment. Comprehensive Psychiatry 46, 453-459.
36. Muthén LK, Muthén BO (2011). Mplus User's Guide, 6th edn. Muthén & Muthén: Los Angeles, CA.
37. Peterson RA, Heilbronner RL (1987). The anxiety sensitivity index: construct validity and factor analytic structure. Journal of Anxiety Disorders 1, 117-121.
38. Rapaport MH, Clary C, Fayyad R, Endicott J (2005). Quality-of-life impairment in depressive and anxiety disorders. The American Journal of Psychiatry 162, 1171-1178.
39. Reiss S, Peterson RA, Gursky DM, McNally RJ (1986). Anxiety sensitivity, anxiety frequency, and the prediction of fearfulness. Behavior Research and Therapy 24, 1-8.
40. Revelle W (2013). psych (version 1.3.2). Evanston, Illinois (http://personality-project.org/revelle.html). Accessed 15 July 2014.
41. Rose RD, Lang AJ, Welch SS, Campbell-Sills L, Chavira DA, Sullivan G, Sherbourne CD, Bystritsky A, Stein MB, Roy-Byrne P, Craske MG (2011). Training primary care staff to deliver a computer-assisted cognitive-behavioral therapy program for anxiety disorders. General Hospital Psychiatry 33, 336-342.
42. Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, Bystritsky A, Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB (2010). Delivery of evidence-based treatment for multiple anxiety disorders in primary care. Journal of the American Medical Association 303, 1921-1928.
43. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R(2000). Quality ofwell being in panic disorder: the assessment of psychiatric and general disability. Journal of Affective Disorders 57, 217-221.
44. Safren SA, Heimberg RG, Brown EJ, Holle C (1996). Quality of life in social phobia. Depression and Anxiety 4, 126-133.
45. Satorra A, Bentler PM (2001). A scaled difference chi-square test statistic for moment structure analysis. Psychometrika 66, 507-514.
46. Sheehan DV (1983). The Anxiety Disease. Scribner: New York.
47. Spitzer RL, Kroenke K, Williams JBW (1999). Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of Mental Disorders. Patient Health Questionnaire. Journal of the American Medical Association 282, 1737-1744.
48. Steiger JH, Lind JC (1980). Statistically based tests for the number of common factors. Paper presented at the Annual meeting of the Psychometric Society, Iowa City, IA.
49. Stein MB, Fyer AJ, Davidson JRT, Pollac MH, Wiita B (1999). Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. American Journal of Psychiatry 156, 756-760.
50. Stein MB, Walker JR, Hazen AL, Forde DR(1997). Full andpartial posttraumatic stress disorder: findings from a community survey. American Journal of Psychiatry 154, 1114-1119.
51. Telch MJ, Schmidt NB, Jaimez TL, Jacquin KM, Harrington PJ (1995). Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. Journal of Consulting and Clinical Psychology 63, 823-830.
52. Tenney NH, Denys DAJP, van Megen HJGM, Glas G, Westenberg HGM (2003). Effect of a pharmacological intervention on quality of life in patients with obsessivecompulsive disorder. International Clinical Psychopharmacology 18, 29-33.
53. Ware JE, Kosinski M, Keller SD (1996). A 12-item short-form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical Care 34, 220-233.
54. West SG, Finch JF, Curran PJ (1995). Structural equationmodels with non-normal variables: problems and remedies. In Structural Equation Modeling: Concepts, Issues, and Applications (ed. R. Hoyle), pp. 56-75. Sage: Thousand Oaks, CA.
55. Wittchen HU, Fuetsch M, Sonntag H, Muller N, Liebowitz M (2000). Disability and quality of life in pure and comorbid social phobia. Findings from a controlled study. European Psychiatry 15, 46-58.
56. Wolitzky-Taylor KB, Arch JJ, Rosenfield D, Craske MG (2012). Moderators and non-specific predictors of treatment outcome for anxiety disorders: a comparison of cognitive behavioral therapy to acceptance and commitment therapy. Journal of Consulting and Clinical Psychology 80, 786-799.